Other
Abaloparatide
Also called Tymlos, BA058
per administration
A human trial worked out how much to take and how often, so a dosing schedule is shown.
Licensed as a medicine in the US and EU.
Quick start
Abaloparatide at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.
- Typical dose
- 80–80 mcg per administration
- How often
- Every day
- Where
- Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
- Time to steady level
- ~9 hours — about five half-lives
- Storage
- Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details
A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.
Work out your draw
These numbers are a starting point — change any of them.
Vial label
Copy this into your label printer.
Published research contexts for Abaloparatide describe 80–80 mcg per administration. Descriptive only, not a recommendation.
A synthetic analog of parathyroid-hormone-related protein, PTHrP(1–34), licensed as a medicine in the US and EU. The ACTIVE study (Miller, JAMA 2016) used a single amount, 80 mcg subcutaneously once daily.
Dosing schedule
How Abaloparatide is commonly stepped up, for reference only.
These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.
| Phase | Amount | Frequency | Route |
|---|---|---|---|
| StandardThe single amount used across the ACTIVE study. | 80 mcg | Once daily | SubQ |
Modelled level — every day
1× is the peak after a single dose.
- Steady-state peak
- 0.99× single dose
- Time to steady state
- 9hours
- Administrations
- 7/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Where these numbers come from
- Miller PD et al., JAMA 2016;316:722 (ACTIVE)Daily subcutaneous 80 mcg versus placebo and open-label teriparatide over 18 months, with new-fracture and bone-density endpoints in postmenopausal osteoporosis research.